icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Dutch regulator fines Italian pharma firm nearly 20 million euros for hiking drug price by more than 30,000%

Dutch regulator fines Italian pharma firm nearly 20 million euros for hiking drug price by more than 30,000%
The Netherlands has ordered an Italian drug maker to cough up nearly 20 million euros ($23.58 million), after the pharma firm inflated the price of one of its medications by an eye-watering 30,000%.

In a decision issued on Monday, the Netherlands Authority for Consumers and Markets (ACM) said that the drug manufacturer, Leadiant, had charged “far too high a price” for a prescription medication used in the treatment of patients with a rare hereditary metabolic disorder known as cerebrotendinous xanthomatosis. Around sixty patients in the country suffer from the disorder, which requires life-long treatment, the ACM said in its statement.

The drug, chenodeoxycholic acid (CDCA), has been in existence for years and was marketed under a variety of names. In 2008, Leadiant acquired a CDCA-based drug from another manufacturer. According to the ACM, at the time the maximum price in the Netherlands for the medication was 46 euros for a package of 100 capsules. A year later, the Italian pharma firm renamed the drug Xenbilox and hiked its price to 885 euros. The price increases continued as Leadiant began to monopolize the CDCA-based drug market in Europe. By 2017, the drug had a price tag of 14,000 euros – sending the cost skyrocketing 30,334% when compared to its 2008 price. 

Also on rt.com All mixed up: It’s more than just an opioid crisis, polydrug use is poisoning Americans

The Dutch regulator imposed a fine of 19,569,500 euros on Leadiant, and condemned the company’s business practices. 

“After a small, low-risk investment, Leadiant implemented a huge price increase for a drug that had already existed for years. In this case, there was no innovation at all. We consider this to be a very serious violation,” Martijn Snoep, head of the ACM, said. 

And it seems that Leadiant now has a low-cost competitor in the Netherlands: In January 2020, the country began domestic production of its own CDCA-based drug. 

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.

Podcasts